ПАЙЛОТ-МАТИАС Тами Дж. (US),КРИШНАН Преетхи (US),КАТИ Уоррен М. (US),КОЛЛИНЗ Кристин А. (US),МИСТРИ Неета К. (US),МАРИНГ Кларенс Дж. (US),ДЕГОЙ Дэвид А. (US),ПРАТТ Джон К. (US),ЛЮ Дачунь (US),ВАГНЕР Р
申请号：
RU2015114566
公开号：
RU2015114566A
申请日:
2013.09.17
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method of treating HCV, comprising administering an effective amount of compound 1 or a pharmaceutically acceptable salt thereof to a patient with HCV, wherein said patient is not genotyped for the treatment. The method of claim 1, wherein said patient is infected with HCV genotype 2.3. The method of claim 1, wherein said patient is infected with HCV genotype 3.4. The method of claim 1, wherein said patient is infected with HCV genotype 4.5. The method of claim 1, wherein said patient is infected with HCV genotype 5.6. The method of claim 1, wherein said patient is infected with HCV genotype 6.7. The method according to any one of paragraphs. 1-6, where the specified compound 1 or its salt is administered together with another anti-HCV agent. 8. The method according to any one of paragraphs. 1-6, where the specified compound 1 is administered together with a HCV protease inhibitor or an HCV polymerase inhibitor. 9. The method according to any one of paragraphs. 1-6, where the specified compound 1 is administered together with a HCV protease inhibitor and a HCV polymerase inhibitor. 10. The method according to any one of paragraphs. 1-6, where the duration of this treatment is less than 24 weeks, and it does not include the introduction of interferon to the specified patient. 11. The method according to any one of paragraphs. 1-6, where the duration of this treatment is not more than 12 weeks, and it does not include the introduction of interferon to the specified patient. 12. The method according to any one of paragraphs. 1-6, wherein said compound 1 is administered together with a HCV protease inhibitor or a combination of a HCV protease inhibitor and a HCV polymerase inhibitor, and the duration of said treatment is less than 24 weeks, and it does not include the administration of interferon to the indicated patient. The method according to any one of paragraphs. 1-6, where the specified compound 1 is administered together with a HCV protease inhibitor or a co
